PYC Physiomics Plc

05 February 2024

Physiomics plc

("Physiomics" or the "Company")

Contract Award

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client, Numab Therapeutics ("Numab"). The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in support of one of Numab's oncology assets entering the clinic and will help inform dose and scheduling decisions.

Dr Peter Sargent, CEO, commented: "We are thrilled to have this opportunity to continue working with and supporting Numab on this asset through its preclinical stages as it heads into the clinic. Along with the project we announced with them in August 2023, this new project is testament to the continued support we provide and the great relationships we've built".

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.